182 related articles for article (PubMed ID: 20103722)
1. Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
Kim ES; Hong WK; Lee JJ; Mao L; Morice RC; Liu DD; Jimenez CA; Eapen GA; Lotan R; Tang X; Newman RA; Wistuba II; Kurie JM
Cancer Prev Res (Phila); 2010 Feb; 3(2):148-59. PubMed ID: 20103722
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer chemoprevention with celecoxib in former smokers.
Mao JT; Roth MD; Fishbein MC; Aberle DR; Zhang ZF; Rao JY; Tashkin DP; Goodglick L; Holmes EC; Cameron RB; Dubinett SM; Elashoff R; Szabo E; Elashoff D
Cancer Prev Res (Phila); 2011 Jul; 4(7):984-93. PubMed ID: 21733822
[TBL] [Abstract][Full Text] [Related]
3. Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung.
Szabo E
Cancer Prev Res (Phila); 2010 Feb; 3(2):128-31. PubMed ID: 20103726
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib decreases Ki-67 proliferative index in active smokers.
Mao JT; Fishbein MC; Adams B; Roth MD; Goodglick L; Hong L; Burdick M; Strieter ER; Holmes C; Tashkin DP; Dubinett SM
Clin Cancer Res; 2006 Jan; 12(1):314-20. PubMed ID: 16397057
[TBL] [Abstract][Full Text] [Related]
5. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.
Hittelman WN; Liu DD; Kurie JM; Lotan R; Lee JS; Khuri F; Ibarguen H; Morice RC; Walsh G; Roth JA; Minna J; Ro JY; Broxson A; Hong WK; Lee JJ
J Natl Cancer Inst; 2007 Nov; 99(21):1603-12. PubMed ID: 17971525
[TBL] [Abstract][Full Text] [Related]
6. Long-term impact of smoking on lung epithelial proliferation in current and former smokers.
Lee JJ; Liu D; Lee JS; Kurie JM; Khuri FR; Ibarguen H; Morice RC; Walsh G; Ro JY; Broxson A; Hong WK; Hittelman WN
J Natl Cancer Inst; 2001 Jul; 93(14):1081-8. PubMed ID: 11459869
[TBL] [Abstract][Full Text] [Related]
7. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
8. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial.
Kurie JM; Lotan R; Lee JJ; Lee JS; Morice RC; Liu DD; Xu XC; Khuri FR; Ro JY; Hittelman WN; Walsh GL; Roth JA; Minna JD; Hong WK
J Natl Cancer Inst; 2003 Feb; 95(3):206-14. PubMed ID: 12569142
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers.
Keith RL; Blatchford PJ; Merrick DT; Bunn PA; Bagwell B; Dwyer-Nield LD; Jackson MK; Geraci MW; Miller YE
Cancer Prev Res (Phila); 2019 Oct; 12(10):721-730. PubMed ID: 31308004
[TBL] [Abstract][Full Text] [Related]
10. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.
Lam S; Mandrekar SJ; Gesthalter Y; Allen Ziegler KL; Seisler DK; Midthun DE; Mao JT; Aubry MC; McWilliams A; Sin DD; Shaipanich T; Liu G; Johnson E; Bild A; Lenburg ME; Ionescu DN; Mayo J; Yi JE; Tazelaar H; Harmsen WS; Smith J; Spira AE; Beane J; Limburg PJ; Szabo E;
Cancer Prev Res (Phila); 2016 Dec; 9(12):906-914. PubMed ID: 27658890
[TBL] [Abstract][Full Text] [Related]
12. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of sulindac for lung cancer chemoprevention.
Limburg PJ; Mandrekar SJ; Aubry MC; Ziegler KL; Zhang J; Yi JE; Henry M; Tazelaar HD; Lam S; McWilliams A; Midthun DE; Edell ES; Rickman OB; Mazzone P; Tockman M; Beamis JF; Lamb C; Simoff M; Loprinzi C; Szabo E; Jett J;
Lung Cancer; 2013 Mar; 79(3):254-61. PubMed ID: 23261228
[TBL] [Abstract][Full Text] [Related]
14. Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers.
Khuri FR; Lee JS; Lippman SM; Lee JJ; Kalapurakal S; Yu R; Ro JY; Morice RC; Hong WK; Hittelman WN
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):311-8. PubMed ID: 11319170
[TBL] [Abstract][Full Text] [Related]
15. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Groen HJ; Sietsma H; Vincent A; Hochstenbag MM; van Putten JW; van den Berg A; Dalesio O; Biesma B; Smit HJ; Termeer A; Hiltermann TJ; van den Borne BE; Schramel FM
J Clin Oncol; 2011 Nov; 29(32):4320-6. PubMed ID: 21990410
[TBL] [Abstract][Full Text] [Related]
16. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G; Meo S; Comella G; Stani SC; Mariani L; Gamucci T; Avallone A; Lo Vullo S; Mansueto G; Bonginelli P; Gattuso D; Gion M
Cancer J; 2005; 11(3):209-16. PubMed ID: 16053664
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
18. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
19. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Arber N; Lieberman D; Wang TC; Zhang R; Sands GH; Bertagnolli MM; Hawk ET; Eagle C; Coindreau J; Zauber A; Lanas A; Levin B
Clin Ther; 2012 Mar; 34(3):569-79. PubMed ID: 22386831
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia.
Lam S; MacAulay C; Le Riche JC; Dyachkova Y; Coldman A; Guillaud M; Hawk E; Christen MO; Gazdar AF
J Natl Cancer Inst; 2002 Jul; 94(13):1001-9. PubMed ID: 12096085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
